MRKR — Marker Therapeutics Share News
0.000.00%
Last trade - 00:00- $16.01m
- $4.68m
- $3.55m
Brief: Marker Therapeutics Appointed Eliot Lurier As Co's Interim CFO
U.S. STOCKS ON THE MOVE-Precision Optics, Tesla, airline stocks
Marker Therapeutics gains as patient dosing begins in cancer therapy study
U.S. STOCKS ON THE MOVE-Catalent, Marker Therapeutics, Genelux
Marker Therapeutics rises as patient dosing begins in cancer therapy study
U.S. STOCKS ON THE MOVE-Centerra Gold, gold miners, Travere Therapeutics
U.S. STOCKS ON THE MOVE-VerifyMe, Intel, Hewlett Packard Enterprise
U.S. STOCKS ON THE MOVE-Nvidia, Trevena, Akili
Marker Therapeutics rises on pre-clinical data from cancer therapy
Marker Therapeutics rises on pre-clinical data from cancer therapy
Brief: Marker Therapeutics Reports Pre-Clinical Data Of T Cell Product Candidate In Lymphoma Cells
Marker Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview
Brief: Marker Therapeutics Appoints Monic Stuart, M.D., As Chief Medical Officer
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini
U.S. STOCKS ON THE MOVE-Minerva Neurosciences, Midwest Holding, Global Payments
U.S. STOCKS ON THE MOVE-Norwegian Cruise Line, Marker Therapeutics, KBR
Marker Therapeutics rises on asset sale deal
Brief: Marker Therapeutics Says On April 27 Peter Hoang, Co's President & CEO, Resigned From His Operating Role, Effective May 1
Brief: Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With Cellready